Your search returned 2 results.

Results
	1.	Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. [electronic resource] by Keystone, Edward C Cohen, Stanley B Emery, Paul Kremer, Joel M Dougados, Maxime Loveless, James E Chung, Carol Wong, Pamela Lehane, Patricia B Tyrrell, Helen Producer: 20130514 In: The Journal of rheumatology vol. 39 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. [electronic resource] by Cohen, Stanley B Emery, Paul Greenwald, Maria W Dougados, Maxime Furie, Richard A Genovese, Mark C Keystone, Edward C Loveless, James E Burmester, Gerd-Rüdiger Cravets, Matthew W Hessey, Eva W Shaw, Timothy Totoritis, Mark C Producer: 20061108 In: Arthritis and rheumatism vol. 54 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search